Introduction
Recently, case-control association studies have come back into favor as a means to uncover the genetic basis of common complex diseases [1] [2] [3] . However, such studies may be undermined by population stratification (PS), resulting in an excess of false-positives. PS is a form of confounding that arises when cases and controls are sampled from genetically distinct populations [4] . PS can still occur if cases and controls are sampled from the same population when the latter is made up of genetically distinct subpopulations [5, 6] . In both situations, the result is that diseased and non-diseased individuals have inherent genetic differences because of the inherent genetic distance between the subpopulations [7] .
PS is potentially a serious problem in association studies [4, 8] and is perhaps the most often cited reason for their non-replicability [9, 10] . Three questions are in order: How can PS in association studies (a) be quantified? (b) be tested for? (c) be corrected for?
In this paper, we provide the first unified approach that is able to answer all three questions within the same statistical framework. In an earlier paper [11] , we derived a quantity ␦ to address the problem of correcting for PS in considerable detail, but there we investigated only Type I errors. Therefore, correcting for PS (issue c) will be mentioned only briefly here for the sake of completeness, although we do describe new simulations for investigating power. In that same paper, we also addressed the issue of quantification of PS through ␦ (issue a). However, our treatment of this issue was incomplete because we had not yet appreciated the full potential of ␦ . Therefore, we will spend some time here further elaborating on the usefulness of ␦ as an ideal measure of PS in case-control association studies, and we will refine some of our conclusions in that paper. New in this paper will also be guidelines for interpreting values of ␦ in case-control association studies. Finally, we will show how PS can be tested for (issue b) by using the estimated value of ␦ , thus providing the missing component in the 'quantifyingtesting-correcting paradigm'. We will describe how to test either for strictly any PS or only PS that is deemed to be practically important. This distinction is important inasmuch as it lies at the heart of one of the conundrums in classical hypothesis testing, namely the inability to demarcate biologically important (or meaningful) results from statistically significant ones (e.g. [12, 13] ). We provide a resolution of this issue here through a method that enables one to a priori decide which values of parameters would be important and then to test only for these. We stress that a full appreciation of the usefulness of ␦ as a unifying, omnibus quantity can be gleaned only by looking at all three problems concomitantly.
Summary of Previous Approaches
Regarding quantifying PS and the extent of its importance in association studies, two quantities have been often used. The first is Wright's F ST [14] which measures the proportionate reduction in heterozygosity in a total population due to subdivision alone [ 15 , p. 319] . Intuitively, the greater the variation in allele frequencies across subpopulations, the more 'population structure' there is, and the larger the value of F ST . For a more thorough discussion of F ST and related 'F -statistics ' , see [15, 16] . The important point to note, however, is that F ST is a function of allele frequencies and subpopulation sampling fractions only, and not of disease prevalences and sample size. The relevance of this observation will become clear in the next paragraph. The second quantity is the confounding risk ratio [CRR; 17 ] , which represents the ratio of the unadjusted (for PS) relative risk of disease to the adjusted relative risk. The larger the confounding effects of PS, the larger the CRR. An excellent treatment of this quantity can be found in [18] . It is useful to note that CRR depends on allele frequencies, disease prevalences and subpopulation sampling fractions, but not on the sample size.
Wacholder et al. [19] used the confounding risk ratio (CRR) to measure the effects of PS, and found that CRR was biased by less than 10% in US studies involving nonHispanic US Causasians of European origin. On the other hand, Heiman et al. [20] correlated CRR with the elevation in false positive rate (FPR), and found that CRR can be a poor predictor of FPR. They also used a standardized measure of the difference of marker allele frequencies which they showed to be highly predictive of FPR. Khlat et al. [21] used both CRR and FPR to gauge the effects of PS, and found PS to be of relatively small concern. Finally and more recently, Xu and Shete [22] quantified the degree of PS through Wright's F ST , and found that PS could be a major problem. However, while CRR does increase with PS, and F ST is an often-used measure of PS, these two measures are inadequate for capturing all the parameters that determine PS in association studies, namely subpopulation marker frequencies, subpopulation disease prevalences, subpopulation sampling fractions, and the case-control sample size [8, 11, 20, 23] . A natural way of quantifying PS in association studies would be in terms of a quantity which would contain all these parameters, and which would predict by how much such PS elevates the FPR in an association study. In what follows, we present such a quantity.
Concerning testing for PS, Pritchard and Rosenberg [24] proposed the use of a panel of biallelic 'null' marker loci (i.e. marker loci not associated with the trait and not in LD with the test locus). A usual 2 test statistic for the cases and controls is calculated for each null marker. Under the null hypothesis of no PS, the sum of the 2 at N null loci has a 2 N distribution. This sum can thus be used as a test statistic for PS. In this paper, we propose an alternative test for PS, when the importance of the latter is gauged by how much it elevates the FPR of the association test relative to its nominal ␣ . Our test has the distinctive property that it can test for either strictly any PS or only PS that is practically important (we explain these two concepts later).
Finally, regarding correcting for PS while performing an association test, two main methods have been proposed. In the first major method, Genomic Control (GC) [25, 26] , the assumption is that, in the presence of PS, the 2 test statistic for association has a standard 1 2 distribution when divided by an appropriate constant . The utility of the method lies in the fact that can be estimated from the empirical distribution of the null loci, usually either as the average of the test statistics at the null loci [27] or as their median divided by 0.456 [25] . To counteract possible anti-conservativeness of GC, Devlin et al. [28] also proposed GCF, which assumes an F 1, L * distribution, instead of 1 2 , where L * is the total number of null loci used. In the second method, Pritchard et al. [29, 30] applied a Bayesian clustering method to a panel of null loci to infer the number of subpopulations and also the subpopulation membership of subjects. This information is then used to perform a test of association. This method is called structured association (SA). Although these methods can perform well, they also have drawbacks. For example, GC assumes that the distribution of the original test statistic can be transformed from a non-central 2 to a central one. However, we showed [11] this assumption is approximately true only for low levels of PS. The second method, SA, is very computationally intensive and can be problematic if the number of subpopulations is misspecified, although improvements have been made by Hoggart et al. [31] . Other recently proposed methods that correct for PS include the use of logistic regression [32] [33] [34] and principal component analysis [35, 36] .
The Unified Approach
Quantifying PS There exists a single quantity that completely captures the confounding effects of PS in a case-control study, when measured by the resulting elevation in FPR of the association test used. Consider any population which is made up of discrete subpopulations. Assume there is no true association between marker genotype (i.e. a genotype containing at least one marker allele) and disease in any subpopulation (we later in this section relax this assumption). For a case-control study with m cases and n controls sampled from the population, suppose we use the standard 2 test (without continuity correction) for association in 2 ! 2 tables: (1) where, at the test locus, a 0 and b 0 are the number of cases with and without the marker genotype, and c 0 and d 0 are the number of controls with these respective genotypes. Let s be the proportion of diseased individuals in the total population with a marker genotype, and t the proportion of nondiseased individuals with a marker genotype. Define [11] . 1 1
Then, for a test with nominal ␣ and reasonably large samples, the inflated FPR due to PS of the 2 test is given by [11] 
where ⌽ (.) is the standard normal distribution function and z ␣ /2 is the ( ␣ /2)th upper percentile of the normal distribution. This relationship is correct to the extent that the use of the 2 test in Equation (1) can be justified, i.e. for reasonably large sample sizes (e.g. no expected frequency in the 2 ! 2 table should be less than 5 [37] ). When there is no PS, ␦ = 0 and FPR = ␣ . In the presence of any PS, ␦ 0 0 and FPR 1 ␣ . The quantity ␦ thus quantifies PS in a case-control association study because it predicts exactly by how much such PS will inflate the FPR of the association test. In this paper therefore, we equate the existence of PS in association studies to the condition that ␦ 0 0. Figure 1 shows some graphs for various test sizes ␣ = 0.01, 0.05 and 0.1. Equation 3 can be used to obtain guidelines for interpreting values of ␦ , at given values of ␣ . Some examples are given in table 1 below for ␣ = 0.001, 0.01, and 0.05. In Appendix A, we also include a Maple program that can be used to estimate ␦ for a given ␣ and FPR.
Based on the derivation of Equation (3) in [11] , we stated there that ␦ can be used as a measure of PS only when there is no true association between disease and marker genotype. In point of fact, this is not completely true because of the way in which ␦ is estimated in a case-control study. We now explain the latter by allowing for the possibility of true associations between marker genotype and disease. Suppose subjects in our case-control study are genotyped at a set of null loci. Recall that, at the test locus, the number of cases and controls with the marker genotype are a 0 and c 0 , respectively. First, estimate t at the test locus by c 0 / n . Next select those null loci whose estimates of t are within, for example, 8 0.15 of c 0 / n . Suppose there are L such loci, and that the number of cases and controls who have been genotyped at the j -th locus are m j and n j , respectively. For the j -th ( j = 1, 2, …, L ) such locus, the estimate of s j is a i / m j , that of t j is c j / n j , and that of ␦ j is
Combining all L matched loci, the overall estimate of ␦ and that of the inflated FPR due to PS are
This shows that, by matching the genotype frequencies of null loci approximately to that of the test locus in the controls, the above method for estimating ␦ ensures that the latter captures only the effect of PS and not that of any true association. Thus, ␦ can be used as a measure of PS when true association between disease and marker genotype is either absent or present, as will be seen later in our simulations of power when correcting for PS.
Testing for PS
Is there a simple way to statistically test for PS in a case-control study? We now propose an alternative test to that of Pritchard and Rosenberg [24] , when the importance of PS is gauged by how much it elevates the FPR of the association test relative to its nominal ␣ . Our test is based on the estimated value of ␦ , and has the distinctive feature that it can test for either strictly any PS or only PS that is practically important. We now explain these two concepts.
Strictly Any PS and Practically Important PS Any ␦ 0 0 implies the presence of PS, so that the twosided test H 0 : ␦ = 0 versus H a : ␦ 0 0 is a test for strictly any PS. However, when performing such a test, we could face a classical dilemma in hypothesis testing [e.g. 12 , 13 ] , where our test could be highly significant, yet hardly practically important. To illustrate, the true value of ␦ could be only 0.01, and statistically significant in a 'large sample,' but of no scientific or practical importance. For example, if ␣ = 0.05, Equation 3 shows that ␦ = 0.01 corresponds to PS that inflates FPR to only 0.0512.
Since, for a given nominal ␣ , we have an explicit relationship (Equation 3) between ␦ and the inflated FPR due to PS of the association test to be used, we can avoid the above-mentioned problem. Depending on how large we allow FPR due to PS to be (relative to the nominal ␣ ), without being practically important, we can determine the magnitude of ␦ (say, ␦ p ) from Equation 3. The test we should then perform is an equivalence test [38] 
This is a test for only PS that is practically important. The choice for ␦ p depends on the nominal ␣ of the association test to be used, on the actual FPR of this association test when there is no PS and no true disease-marker association, and on the perceptions of the investigator. For example, if ␣ = 0.05, the investigator might regard an inflated FPR due to PS of up to 0.07 to be practically unimportant and therefore use ␦ p = 0.416 (obtained from Equation 3) in the test for PS. On the other hand, if ␣ = 0.01, and only FPR 1 0.014 is to be regarded as practically important, then ␦ p = 0.323 should be used.
Statistical Tests
Let us assume that the L selected matched loci are in linkage equilibrium with each other. (This is likely to be true if, for example, SNPs at a distance ϳ 1 cM from each other are chosen as the null markers). The test for strictly no PS is two-sided. Under H 0 : (i) Depending on the nominal ␣ of the association test, decide how large the inflated FPR due to PS can be.
(ii) Determine the corresponding ␦ p from Equation 3 by using the program in Appendix A or contacting the first author (P.G.).
(iii) For a test of size ␣ , reject the null hypothesis of practically important PS if the (1-2 ␣ ) confidence interval for the true ␦ falls completely within the 'zone of indifference' (-␦ p , ␦ p ) [38] , i.e. if 1 1 and .
Note: (a) because this is an equivalence test, the null and alternative hypotheses have been switched: the alternative hypothesis is that of equivalence (i.e. PS is practically unimportant); (b) the equivalence test based on Equation 6b above has significance level ␣ , as required, rather than 2 ␣ [see 39 , p 172]. (7) has the standard 2 1 distribution, where:
Correcting for PS
T * DC is therefore the association test statistic that corrects for PS. We have called this method ␦ -centralization (DC). It is computationally simpler that SA and, unlike GC, its validity does not depend on the degree of confounding due to PS (i.e. on the value of ␦ ).
Simulations
We performed computer simulations in order to investigate Type I errors and power. We first describe how the candidate locus and null loci were generated in a discrete population substructure model. We assume there is no true association between marker genotype and disease in each subpopulation. Using a given value of p k as the marker allele frequency at the test locus in both cases and controls in subpopulation k ( k = 1, 2, …, K ) , the allele frequency ( p jk ) of the j -th null locus in subpopulation k was generated from a 1 1 Beta 
Here k , d k , and r jk are the subpopulation sampling fraction, disease prevalence and marker genotype frequency at the j -th null locus (calculated from p jk by assuming Hardy-Weinberg equilibrium) of the k-th subpopulation. Let a j and c j be the number of cases and controls, respectively, having the marker genotype at the j -th locus. The values s j and t j for the j -th null locus were used to generate a 2 ! 2 table at that locus, since a j ϳ Bin( m j , s j ) and c j ϳ Bin( n j , t j ). Once these tables were generated, confounding due to PS was quantified, tested and corrected for, using the methods as we described above. If we assume there is true association between marker genotype and disease in each subpopulation, we then use a different marker genotype frequency between diseased and non-diseased subjects in each subpopulation. For comparison purposes, we applied DC, GC and GCF (see tables 4 and 5 ). Comparisons were done for increasing values of ␦ . We performed the above simulations to compare the operating characteristics of the t test for strictly no PS in Equation 6a ( table 2 ) and for practically unimportant PS  in Equation 6b ( table 3 ) . In the latter case, we allowed an FPR of up to 0.07 to be practically unimportant (at ␣ = 0.05) and therefore used ␦ p = 0.416. Table 2 shows that matching to within 8 0.15, rather than 8 0.1, gives the t test better operating characteristics. Thus the T-statistic in Equation 6a fails to have the nominal Student's t-distribution when matching is too narrow. Table 3 shows that power is relatively high for very small ␦ ( ; 0 to 0.1), but starts decreasing for 0.2 ^ ␦ ! 0.416.
Simulation results comparing DC, GC and GCF are shown in tables 4 and 5 . The performance of GC depends very much on the degree of confounding, i.e. on the value of ␦ . With increasing ␦ , GC becomes more and more conservative. At ␦ = 0.5, GC performs well, but at ␦ = 1.0 it becomes over-conservative, rejecting at an average rate of about 2.5% for a nominal ␣ = 0.05. The situation is worse for larger ␦ [see also 40 ] . Concerning power, GC seems to lose considerable power only for ␦ 1 2.0. In all these situations, DC performs well with respect to both Type I and Type II errors. GCF always has a smaller rejection rate than GC since it is based on an F 1, L* distribution, instead of 2 1 , and F 1, L * 1 2 1 for all L * . Therefore when GC is either overconservative or 'low-powered', GCF is even more so.
Discussion
PS in association studies cannot be disregarded outright and may be a major reason why many positive findings fail to replicate. In this paper, we have provided, for the first time, one statistical framework that is able to address all aspects of PS in case-control association studies: we have shown that, through an omnibus quantity ( ␦ ), PS can be (a) quantified, (b) tested for, and (c) corrected for. We summarize our findings for these three issues in turn.
Summary of Results for the Three Issues
The quantity ␦ is ideally suited as a measure of PS (issue a) in case-control association studies. This is because, by estimating ␦ , one is able to exactly predict by how much PS in a case-control study inflates the FPR of an association test relative to its nominal ␣ (see Equation 3 and fig. 1 ). In general, for a given ␣ , FPR (and hence the extent of PS) increases with the magnitude of ␦ . Moreover, we can use Equation 3 to better interpret values of ␦ (see table 1 ): for example, at ␣ = 0.05, a ␦ of size 0.416 (or less) is small because it corresponds to an inflated FPR of the association test of only 0.07, a ␦ of size about 0.653 is medium (the FPR is twice the nominal ␣ ), and a ␦ of size 1.115 (or more) is large (the FPR is four times the nominal ␣ ). We stress that ␦ is not a global measure of stratification between subpopulations; rather, it is a locus-specific measure. A global measure of PS cannot correctly indicate the extent to which a test for association will be affected by PS at a particular locus because the 'global' difference between allele frequencies at several markers will often be significantly different from a 'locus-specific' difference. Therefore, our argument is, since we are considering association tests performed on a locus-to-locus basis, a correct measure of PS for an association study should be a local measure, specific to the locus being tested for association. Thus, ␦ is not intended as a replacement of global measures of population structure such as F ST .
We make three additional observations: (i) From Equation 3, we note that the value of ␦ must be used in conjunction with the nominal ␣ of the association test when gauging the extent of PS. ) is tripled relative to the nominal ␣ (a relative increase of 200%); however, the same ␦ = 0.4 is 'very small' when ␣ = 0.05 because the FPR is only 0.0685 (a relative increase of only 37%). (ii) A second point regards a statistical connection of ␦ : in [11] we showed that, in the presence of PS and in the absence of any true association, 2 test in Equation 1 has a non-central 2 distribution with 1 degree of freedom and approximate non-centrality parameter ␦ 2 . (iii) The third observation concerns a desirable relationship between ␦ and sample size: from Equation 2, we see that, for a fixed value of the numerator s -t (which can be thought of as a measure of the inherent genetic distance between diseased and non-diseased individuals due to subpopulations), ␦ and hence the confounding effect of PS can be made arbitrarily large by increasing the number of cases and controls. This is a classic case whereby bias is made even worse by increasing the sample size [5, 20, 41, 42] . This is because, in essence, the biased procedure is actually testing a different null hypothesis, so increasing the sample size raises the 'power' to reject that null hypothesis. Our second use of ␦ relates to the testing for PS (issue b). We have shown how to test for either strictly any PS or only PS that is practically important PS. By practically important PS, we mean PS that inflates the FPR of an association test beyond a certain amount, relative to its nominal ␣ . By deciding how big an FPR is large enough, relative to the nominal ␣ , one can use Equation 3 to estimate the corresponding ␦ p and perform an equivalence test for practically important PS. Our guidelines are to use ␦ p = 0.416 when ␣ = 0.05, corresponding to an inflated FPR of 0.07 due to PS, and ␦ p = 0.323 when ␣ = 0.01, corresponding to an inflated FPR of 0.014 due to PS. Of course, all of this assumes that the association test used has an FPR close to the nominal ␣ when there is no PS and no true association [43] , and to this end we recommend using a 2 without continuity correction. This is because the latter has an FPR close to the nominal ␣ , as opposed to the 2 with continuity correction whose FPR is much less than ␣ [e.g., see 44 , p. 137]. Since both quantifying PS and testing for practically important PS depend on the nominal ␣ of the association test to be subsequently performed, it is also natural to ask how to do either of these if the aim is only to quantify or test, and not correct later. Here, we suggest assuming the most widely used value of ␣ , namely 0.05, for both quantifying, and testing by calibrating ␦ p accordingly.
Our third use of ␦ concerns correcting for PS (issue c) while performing an association test (see Equation 8 ). The method we have proposed (DC) works by directly centralizing the test statistic which has a standard normal distribution. DC is similar to GC in that both use null loci as 'genomic controls'. However, unlike GC, DC is valid for all levels of PS (i.e. all values of ␦ ) and is also computationally simpler than SA. Finally, if narrow frequency matching is performed, as few as 25 matched null loci are enough for DC to perform well [11] .
Concluding Remarks
Since our unified approach depends on ␦ , it is crucial that this quantity be accurately estimated in any case- Table 5 . Correcting for PS: Type I error and power of GC, GCF and DC (to detect any true association) with 3 subpopulations control study. We have shown how this can be done by genotyping both cases and controls at a set of null marker loci (preferably SNPs), and then selecting those null loci whose marker genotype (hence allele) frequencies in the controls closely match those of the test locus in the controls. A value of ␦ can be estimated from each matched null locus, and by averaging, an overall estimate of ␦ can be obtained. It is thus important that there is a sufficiently large number of controls so that genotype (or allele) frequencies can be accurately estimated at both the test and null loci. Moreover, since ␦ is obtained by matching, the methods in our unified approach (quantifying, testing, and correcting) are independent of the probability distribution used for generating loci across the genome. Finally, the method of frequency matching by using controls ensures that ␦ is a measure of PS either in the presence or absence of any true association between disease and marker genotype.
Although the distribution of the estimated ␦ values at all null loci is approximately normal, that of the matched null loci is roughly uniform. This has an important implication regarding the tests for PS in Equations 6a and 6b, being both based on the Student's t -distribution. These tests essentially rely on the Central Limit Theorem (CLT) and, as such, their validity depends on the number of matched loci ( L ) being large enough. Moreover, our simulations ( table 1 ) show that if the matching is too strict ( 8 0.1) the CLT does not hold and the t-test in Equation 6a becomes over anti-conservative. When matching is done to within 8 0.15, the CLT is more applicable and the t test has correct error rates. As far as correcting for PS is concerned, the narrower the matching window, the more accurate the estimation of ␦ . However, this also means more null loci will have to be genotyped before the suitable ones are found. In general, we recommend a matching window of 8 0.15, since both the test for the PS and the correction for PS then have good operating characteristics.
Should we always test for PS first and then decide whether to apply the DC method or use an uncorrected test-statistic based on the result of the first test? There are at least three problems with such an approach: (i) if a Type I error is made in the test for strictly no PS, then using the DC method for association will result in loss of power; (ii) if a Type II error is made in the test for strictly no PS, then using an uncorrected test for association will result in an increased FPR; (iii) finally, if PS is declared practically unimportant and an association test is performed without correcting for it, the FPR of the association test will increase. Another fact is that most practitioners will feel safer to estimate ␦ and then directly move to correct for PS, without necessarily going through the testing phase. We therefore advocate flexibility in using the unified approach: testing and correcting could best be thought as independent tasks, and there is no need to do one before the other, once ␦ is estimated.
An important topic concerns the issue of multipletests performed in genome-wide association studies [45] [46] [47] [48] . Here the danger is that of a rapid rise in the experimentwise error-rate because of the large number of test loci. On the other hand, a Bonferroni-correction approach results in the opposite problem: substantial loss in power because the typical test size is ϳ 10 -6 [2] . A reasonable compromise can be achieved through: (i) Benjamini and Hochberg's FDR procedure [49] if no correlation between loci is allowed for, (ii) variants of the FDR procedure [e.g. 50 ] if possible correlation between loci is allowed for. We therefore recommend applying the FDR or its variants when either testing or correcting for PS for a large number of loci.
It is also important to note the genetic model we have used here. We have assumed a dominant genetic model (in the sense that the genotypic relative risk for disease is the same if the genotype at the test locus has one or two marker alleles), and both the definition of ␦ in Equation  2 
